As the precision medicine field evolves and the science behind personalized therapies for complex conditions surges ahead, reimbursement models are racing to catch up. Precision medicine treatments, like cell and gene therapies, tend to have high price tags and novel delivery mechanisms. This makes creating effective payment models for these therapies a challenge, but drug developers and payers are working together to create out-of-the-box solutions.
Determining prices for breakthrough cell and gene therapies is a complicated process, said Laura Okpala, director of reimbursement policy at Gilead Sciences, at the MedCity INVEST Precision Medicine conference. Though there is a strong belief that the pricing process needs to be driven by value value means different things to different people. Biopharmaceutical companies, like Gilead Sciences, must consult with various stakeholders, including patients, caregivers and payers, who all have different perspectives on value.
Part of why the pricing is so difficult is because of the inherent complexities in the healthcare system, Okpala said. When we think of traditionally how drugs are paid for, were thinking about chronic treatment, were thinking about treatment over a long, extended period, treatment over and over again, reimbursement every single time, and that adds up.
But when you think about cell and gene therapies, all those costs and all of that treatment happens upfront, she added. And then you get that durable response, up to four years at this point. And that is really a paradigm shift when you think about [a] healthcare system that really isnt set up to deal with that upfront cost and that value delivered over time.
But the upfront payment is just one of many challenges. Mark Trusheim, strategic director of the NEWDIGS initiative at the MIT Center for Biomedical Innovation, said at the virtual conference that there are two more key challenges that arise: the performance uncertainty regarding these therapies, particularly around their durability, and the actuarial uncertainty it causes for payers. Most of these therapies are for rare conditions, so a single high-cost therapy in any given month can have a negative impact on payers income statements.
To combat these challenges, several innovative reimbursement models have been developed.
One is a model based on treatment milestones. Per this model, a certain amount of money is paid upfront, and if the therapy doesnt show the intended effects in certain predetermined timeframes, the drug developer pays back a portion of the initial payment.
[The model allows] some risk sharing between the developer and the payer, so they dont have to argue quite so much up front, Trusheim said. And the actual product performance [resolves] how much [is] finally the net reimbursement or the net price for that therapy.
This model helps manage the different expectations and fears of both parties, he added.
Another is a subscription-based model, which includes a fixed fee for unlimited access to certain therapies, Trusheim explained. Cigna has an insurance product that offers this reimbursement model, where plan members contribute a certain amount each month that is used to pay for therapies as needed. Cigna takes on the risk, guaranteeing that they will provide as much therapy as the members require.
This model is a great example of how payers can manage the actuarial fluctuation that occurs when funding cell and gene therapies, Trusheim said. But it comes with its challenges, because in some cases, its difficult to ascertain the eligible population for a particular therapy especially if there are alternate therapies already available.
But Trusheim is confident that innovation in reimbursement will catch up to clinical innovation in the precision medicine arena.
Were now in an era where innovation in payment structures and approaches are beginning to match the kind of innovation we have in the transformative science for patients, he said. Successfully providing patient access and benefit requires both kinds of innovation, not just scientific innovation. The creativity is there we are going to succeed. Just as the science has succeeded, the payment innovation is also moving forward and having success.
Photo credit: Devrimb, Getty Images
View post:
Innovative payment models to support cell and gene therapies on the rise - MedCity News
- Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and ... - PR Newswire - March 18th, 2024
- 3 Precision Medicine Stocks That Could Benefit From the Industry's Rise - InvestorPlace - March 18th, 2024
- Prime Editing Approach Provides a Faster, More Effective Way to Screen for Cancer Mutations - Inside Precision Medicine - March 18th, 2024
- Global Genomics Industry Research 2024-2031: Rising Adoption of Personalized Medicines and Gene Therapies ... - PR Newswire - March 18th, 2024
- CAR T-Cell Therapy Successfully Used to Treat Brain Tumors - Inside Precision Medicine - March 18th, 2024
- Revolutionizing Wellness: The Power of Personalised Health Tech - AutoGPT - March 18th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- AI and predictive medicine: Recent advances - News-Medical.Net - March 10th, 2024
- Personalized medicine is coming, but who will have access to it? - AAMC - March 10th, 2024
- Why personalized medicine is a business trend to watch in 2024 - HealthLeaders Media - March 10th, 2024
- AI helps cardiologists deliver personalized healthcarebut there is still plenty of work to do - Cardiovascular Business - March 10th, 2024
- Q&A: How AI and wearable technologies are transforming medicine - EMS1.com - March 10th, 2024
- HealthTech Revolution: Wearables, AI, and the Personalized Future of Healthcare - GearBrain - March 10th, 2024
- Redefining Healthcare: The Rise of Personalized Medicine and the Shift from Conventional Care - Medriva - March 10th, 2024
- Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer - OncLive - March 10th, 2024
- Chemotherapy Plus High Doses of Radiation Effective for Treating Non-Small Cell Lung Cancer - Inside Precision Medicine - January 17th, 2024
- It's Time to Fully Embrace Precision Medicine's Promise in Pediatrics - Healthcare Innovation - January 17th, 2024
- Special Report: Radiation Oncology Takeaways from RSNA23 - Imaging Technology News - January 17th, 2024
- Advanced Therapeutics Pharmaceutical Outsourcing Market to Surge at a CAGR of 4.4% by 2034 Amid Growing ... - PR Newswire - January 17th, 2024
- Simulations of the human body and advanced data promise more personalized medical treatment - Medical Xpress - January 17th, 2024
- United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive ... - PR Newswire - January 17th, 2024
- Advances Usher In Era of Personalized Treatment for Obesity - Gastroenterology & Endoscopy News - January 17th, 2024
- Unveiling the Reality of Personalized Medicine: Yale Study Highlights Limitations in Current Predictive Models - Medriva - January 17th, 2024
- Digital Twins: The Future of Personalized Healthcare - BNN Breaking - January 17th, 2024
- Healthcare in 2024: A Vision of the Future | Future of Healthcare Predictions - Medriva - January 17th, 2024
- Utilization of the microbiome in personalized medicine - Nature.com - December 22nd, 2023
- Focusing on Women's Health - Inside Precision Medicine - December 22nd, 2023
- Revolutionizing Healthcare: Innovations in Regenerative Medicine Offer Hope - Inside Precision Medicine - December 22nd, 2023
- AI in Genomics Market Predicted to Grow at CAGR of 40.6% by 2031, with Revenue $9.8 Billion - PharmiWeb.com - December 22nd, 2023
- Innovative Technologies Transforming Cancer Treatment - BNN Breaking - December 22nd, 2023
- Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com - December 22nd, 2023
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022